Zimmer Biomet stock heads into the open after a 2.4% drop
Published on 09/11/2026 at 07:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zimmer Biomet stock closed at USD 92.30 on the New York Stock Exchange on September 10, 2026, down 2.44% from the prior session according to exchange data summarized by MarketBeat. The shares moved between a day high and low consistent with that closing level and finished the day on solid trading volume compared with recent sessions.
September 10, 2026 in numbers
Zimmer Biomet Holdings Inc. (ISIN US98956P1021, NYSE: ZBH) ended the September 10, 2026 session at USD 92.30, a decline of 2.31 points or 2.44% from the previous close, per New York Stock Exchange pricing data reported by MarketBeat. After hours, the stock was indicated at USD 93.07, 0.84% above the official close, in electronic trading that followed the regular session. The closing level left Zimmer Biomet shares clearly above a recent 52-week low referenced at USD 79.12 in an earlier market summary, while the loss came in a broader equity market environment that also saw major United States indices under pressure on September 10, 2026, with the Dow Jones Industrial Average losing 0.8% that day as reported by Yahoo Finance. Intraday trading in Zimmer Biomet reflected a range that kept the close between the day high and low, and overall turnover in the shares stayed in line with recent averages.
Recent news flow has added context around the stock. On September 8, 2026, Zimmer Biomet stock was reported at USD 94.22 on the New York Stock Exchange with commentary highlighting that the shares were USD 15.10 above the 52-week low at that point, according to a wrap from Ad-hoc-news. The same report pointed to earlier guidance commentary and planned job reductions as factors weighing on investor sentiment. Separately, a piece from Swissinfo on September 10, 2026 discussed Zimmer Biomet’s plan to cut up to 580 jobs at its site in Winterthur, Switzerland, a restructuring move that forms part of the backdrop for trading in the shares.
Today’s focus for Zimmer Biomet stock
Today, Zimmer Biomet enters the United States trading session without a scheduled earnings release on September 11, 2026 in the available calendars, but investors remain attentive to ongoing restructuring developments and to broader healthcare sector sentiment. Analyst coverage has recently highlighted the stock’s prospects, with a report cited by The Globe and Mail summarizing recent views on Zimmer Biomet and peers and pointing to a Moderate Buy consensus and an average price target around USD 106.07, adding a valuation reference point ahead of the open. Broader market conditions, including the prior session’s decline in the Dow Jones Industrial Average and sector performance in medical devices as captured in United States market wraps, are likely to provide additional context for Zimmer Biomet stock when trading resumes today.
